PRO 2000
| Clinical data | |
|---|---|
| Other names | 2-Naphthalenesulfonic acid, sodium salt, polymer with formaldehyde |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider |
|
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.111.201 |
| Chemical and physical data | |
| Formula | (C10H8O3S.CH2O.Na)x |
| Molar mass | Approximately 5 kg/mol |
PRO 2000 is an experimental vaginal microbicide which has been proposed as a preventative medicine for reducing the risk of contracting HIV. It has never been recommended as an effective medicine to be used for any purpose. Some clinical trials have shown that under some conditions it may provide some protection against HIV.
History
Endo Pharmaceuticals manufactures the drug.[1]
Efficacy
Animal testing studies done on macaques have shown that PRO 2000 is effective in preventing the transmission of HIV. Other studies have given supportive evidence that the product is safe in humans and would be an appropriate candidate for testing.[2]
A phase III clinical trial of 9385 women in sub-Saharan Africa showed that PRO 2000 was not effective in preventing transmission of HIV.[3]
References
- ^ "AIDSinfo - HIV/AIDS Drug Information - PRO 2000". aidsinfo.nih.gov. 2011. Archived from the original on October 17, 2011. Retrieved 20 November 2011.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ Patton, D. L.; Cosgrove Sweeney, Y. T.; Paul, K. J. (2008). "A Summary of Preclinical Topical Microbicide Vaginal Safety and Chlamydial Efficacy Evaluations in a Pigtailed Macaque Model". Sexually Transmitted Diseases. 35 (10): 889–897. doi:10.1097/OLQ.0b013e31817dfdb8. PMID 18607310.
- ^ McCormack, S.; Ramjee, G.; Kamali, A.; Rees, H.; Crook, A. M.; Gafos, M.; Jentsch, U.; Pool, R.; Chisembele, M.; Kapiga, S.; Mutemwa, R.; Vallely, A.; Palanee, T.; Sookrajh, Y.; Lacey, C. J.; Darbyshire, J.; Grosskurth, H.; Profy, A.; Nunn, A.; Hayes, R.; Weber, J. (2010). "PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial". The Lancet. 376 (9749): 1329–37. doi:10.1016/S0140-6736(10)61086-0. PMC 2956883. PMID 20851460.